Eribulin regresses a cisplatinum-resistant rare-type triple-negative matrix-producing breast carcinoma patient-derived orthotopic xenograft mouse model

Jun Yamamoto, Takuya Murata, Norihiko Sugisawa, Takashi Higuchi, Yoshihiko Tashiro, Hiroto Nishino, Sachiko Inubushi, Yu Sun, Hyein Lim, Kentaro Miyake, Koichiro Shimoya, Tsunehisa Nomura, Junichi Kurebayashi, Hirokazu Tanino, Chihiro Hozumi, Michael Bouvet, Shree Ram Singh, Itaru Endo, Robert M. Hoffman

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Background/Aim: Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triplenegative breast cancer (TNBC). In the present report, we determined the drug sensitivity for a triple-negative MPBC using a patient-derived orthotopic xenograft (PDOX) model. Materials and Methods: The PDOX model was established in the left 2nd mammary by surgical orthotopic implantation (SOI). MPBC PDOX models were randomized into 4 groups (6 mice per group) when the tumor volume became 80 mm3: G1, control group; G2, cisplatinum group [intraperitoneal (i.p.) injection, weekly, for 2 weeks]; G3, paclitaxel group (i.p., weekly, for 2 weeks); G4, eribulin group [intravenous (i.v.) injection, weekly, for 2 weeks]. All mice were sacrificed on day 15. Tumor volume and body weight were measured one time per week. Results: The MPBC PDOX model was resistant to cisplatinum (p=0.800). Paclitaxel suppressed tumor growth compared to the control group (p=0.009). However, only eribulin regressed the tumor (p=0.001). Conclusion: Eribulin has clinical potential for triple-negative MPBC patients.

Original languageEnglish
Pages (from-to)2475-2479
Number of pages5
JournalAnticancer research
Volume40
Issue number5
DOIs
Publication statusPublished - 2020 May
Externally publishedYes

Keywords

  • Cisplatinum
  • Eribulin
  • Matrix-producing breast carcinoma
  • PDOX
  • Patient-derived orthotopic xenograft
  • TNBC
  • Triple-negative breast cancer
  • Tumor regression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Eribulin regresses a cisplatinum-resistant rare-type triple-negative matrix-producing breast carcinoma patient-derived orthotopic xenograft mouse model'. Together they form a unique fingerprint.

Cite this